Clinical Trials Logo

Infectious Mononucleosis clinical trials

View clinical trials related to Infectious Mononucleosis.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT06002802 Completed - Clinical trials for Epstein-Barr Virus Infections

Study on Infectious Mononucleosis in Munich

IMMUC
Start date: March 1, 2016
Phase:
Study type: Observational

This observational clinical study aims at the identification of novel biomarkers and causative factors of complicated and/or protracted Epstein-Barr virus-associated infectious mononucleosis (IM). Clinical, biochemical, and routine virological data were collected from 200 patients with IM, novel analytical tools were implemented, and immunological and virological experimental data were generated using blood samples and mouthwashes. Patients have been investigated within four weeks after the onset of symptoms as well as one month and six months thereafter.

NCT ID: NCT00575185 Completed - Clinical trials for Infectious Mononucleosis

Activity of Valomaciclovir in Infectious Mononucleosis Due to Primary Epstein-Barr Virus Infection

Mono6
Start date: November 2007
Phase: Phase 1/Phase 2
Study type: Interventional

This will be a randomized, placebo-controlled, double-blind single-center proof of concept study to evaluate the anti-EBV activity of 4 grams of valomaciclovir (2 grams BID) for 21 days in subjects with infectious mononucleosis documented to be caused by primary EBV infection. Otherwise healthy subjects (≥15 years old) referred to us with a clinical diagnosis of primary infectious mononucleosis will be screened and those with laboratory-confirmed primary EBV infection will be enrolled.

NCT ID: NCT00274404 Completed - Clinical trials for Infectious Mononucleosis

Controlled Trial of Valacyclovir in Infectious Mononucleosis

Start date: February 2004
Phase: Phase 1/Phase 2
Study type: Interventional

The hypothesis is that an antiviral drug (valacyclovir) will reduce the amount of Epstein-Barr virus (EBV) in the mouths of university students with infectious mononucleosis (mono) while being a safe drug. Because EBV is the cause of mono, it is expected that reduction of the amount of virus could result in faster recovery from the disease.